Dual Targeting of Akt and MAPK Pathways With Capivasertib and B‐Raf Inhibitors Synergistically Suppresses Tumor Growth in B‐Raf‐Mutated Melanoma Models
Fundamental & Clinical Pharmacology · 2026-05 · 40 (3)
DOI: 10.1111/fcp.70088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 21.04.2026. Verfasst von Jun Tang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Proto-Oncogene Proteins B-raf, Melanoma, Protein Kinase Inhibitors. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Xiangyang Science and Technology Research and Development Project.
Abstract (Originalsprache)
Resistance to B‐Raf inhibitors in melanoma poses a significant challenge to effective treatment. This study investigates the synergistic effects of capivasertib, an Akt pathway inhibitor, in combination with B‐Raf inhibitors (vemurafenib and encorafenib) in B‐Raf‐mutated melanoma models. Combination index analysis demonstrated strong synergy between capivasertib and B‐Raf inhibitors in melanoma cells. In contrast, combinations of capivasertib with standard chemotherapeutics were antagonistic, underscoring the specificity of the interaction. Mechanistic studies revealed that capivasertib effectively suppressed Akt signaling. Synergism was abolished in Akt‐overexpressing cells, confirming Akt's role in the observed combination effects. The combination treatments significantly reduced tumor growth, with tumor volumes in the capivasertib‐vemurafenib and capivasertib‐encorafenib groups reduced by ~70% relative to control. Notably, this inhibition was sustained for at least 8 weeks, with tumors in the combination groups remaining minimal, while those in the control group reached maximal size by Week 4. Systemic toxicity analyses revealed no significant changes in body weight or serum markers of pancreatic, kidney, or liver function. These findings establish capivasertib and B‐Raf inhibitor combinations as a safe and effective strategy for overcoming resistance B‐Raf‐mutated melanoma, providing new insights into the potential of dual pathway targeting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei, China.
- Department of Dermatology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei, China.
ORCID-Profile: Lingling Zhao, Baoxue Duan
Förderung
- Xiangyang Science and Technology Research and Development Project
Zitieren
APA
Tang, J., Zhao, L., Zhu, Y., & Duan, B. (2026). Dual Targeting of Akt and MAPK Pathways With Capivasertib and B‐Raf Inhibitors Synergistically Suppresses Tumor Growth in B‐Raf‐Mutated Melanoma Models. Fundamental & Clinical Pharmacology, 40(3). https://doi.org/10.1111/fcp.70088
Vancouver
Tang J, Zhao L, Zhu Y, Duan B. Dual Targeting of Akt and MAPK Pathways With Capivasertib and B‐Raf Inhibitors Synergistically Suppresses Tumor Growth in B‐Raf‐Mutated Melanoma Models. Fundamental & Clinical Pharmacology. 2026;40(3). doi:10.1111/fcp.70088
BibTeX
@article{Tang2026,
author = {Tang, Jun and Zhao, Lingling and Zhu, Yuanyuan and Duan, Baoxue},
title = {Dual Targeting of Akt and MAPK Pathways With Capivasertib and B‐Raf Inhibitors Synergistically Suppresses Tumor Growth in B‐Raf‐Mutated Melanoma Models},
journal = {Fundamental & Clinical Pharmacology},
year = {2026},
volume = {40},
number = {3},
doi = {10.1111/fcp.70088}
}
EUVIMED